196 related articles for article (PubMed ID: 37324392)
1. Clinical value of fecal calprotectin for evaluating disease activity in patients with Crohn's disease.
Li J; Xu M; Qian W; Ling F; Chen Y; Li S; Cheng Y; Zhu L
Front Physiol; 2023; 14():1186665. PubMed ID: 37324392
[No Abstract] [Full Text] [Related]
2. Impact of disease location on fecal calprotectin levels in Crohn's disease.
Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
5. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease.
Zhou S; Huang Z; Hou W; Lin Y; Yu J
Inflamm Res; 2024 Feb; 73(2):199-209. PubMed ID: 38168701
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity.
Zittan E; Kelly OB; Gralnek IM; Silverberg MS; Hillary Steinhart A
JGH Open; 2018 Oct; 2(5):201-206. PubMed ID: 30483590
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between contrast-enhanced ultrasound parameters and Crohn's disease activity].
Zhang YY; Yuan T; Wang CW; Wang L; Zhang HJ; Wang YL
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):427-432. PubMed ID: 37032139
[No Abstract] [Full Text] [Related]
9. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
10. Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn's Disease: A Retrospective Cohort Study.
Ye L; Cheng W; Chen BQ; Lan X; Wang SD; Wu XC; Huang W; Wang FY
Sci Rep; 2017 May; 7(1):1970. PubMed ID: 28512287
[TBL] [Abstract][Full Text] [Related]
11. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn's disease evaluated by double-balloon endoscopy.
Han W; Wu J; Zhang P; Hu N; Mei Q; Hu J
Int J Colorectal Dis; 2022 Sep; 37(9):1953-1961. PubMed ID: 35927341
[TBL] [Abstract][Full Text] [Related]
13. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
Zubin G; Peter L
Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
[TBL] [Abstract][Full Text] [Related]
14. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
15. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
16. LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease.
Kuai XY; Yu SY; Cui XF; Zhao XJ; Mao XQ; Yu Y; Hu T; Zhang HJ; Zhou CL
Gastroenterol Res Pract; 2021; 2021():5557357. PubMed ID: 34621310
[TBL] [Abstract][Full Text] [Related]
17. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy.
Kawashima K; Ishihara S; Yuki T; Fukuba N; Sonoyama H; Kazumori H; Yamashita N; Tada Y; Kusunoki R; Oka A; Oshima N; Mishima Y; Moriyama I; Kinoshita Y
Inflamm Bowel Dis; 2017 Nov; 23(11):2027-2034. PubMed ID: 28817462
[TBL] [Abstract][Full Text] [Related]
18. Fecal miR-223 is a noninvasive biomarker for estimating Crohn's disease activity.
Zhang J; Guo Z; Wang Z; Zhu W; Li Q
Immun Inflamm Dis; 2023 Dec; 11(12):e1131. PubMed ID: 38156390
[TBL] [Abstract][Full Text] [Related]
19. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
20. Elevated Levels of IL-27 Are Associated with Disease Activity in Patients with Crohn's Disease.
Cui X; Jiao C; Wang D; Ye Z; Ma J; Tang N; Zhang H
Mediators Inflamm; 2021; 2021():5527627. PubMed ID: 34744512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
